Sanofi/Organon Arixtra
Executive Summary
Arixtra added to 425 hospital formularies in the U.S. and Europe as of July, Sanofi says. Sanofi/Organon launched Arixtra (fondaparinux) for deep vein thrombosis in the first quarter (1"The Pink Sheet" Dec. 17, 2001, p. 3). While Arixtra sales had a slow start in the first half, "formulary wins are in line with expectations," Sanofi said. The company expects Arixtra to gain full access to the low molecular weight heparin market in 2006; Sanofi estimates its approved use in hospital-based orthopedic surgery provides 14% access...
You may also be interested in...
Organon/Sanofi Arixtra Late January Launch Will Be Supported By 240 Reps
Organon and Sanofi-Synthelabo will launch the injectable antithrombotic Arixtra with 240 sales reps in late January
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.